A liquid veterinary composition for use in the protection and treatment of parasite infestations of cattle animal comprising an effective amount of at least one isoxazoline compound of formula wherein R 1 = halogen, CF 3, OCF 3, or CN; n = integer from 0 up to and including 3; m = 1 or 2; R 2 = C 1 -C 3 haloalkyl; T = ring structure: 5-, or 6-membered, or bicyclic, which is optionally substituted by one or more radicals Y; Y = methyl, halomethyl, halogen, CN, NO 2, NH 2 -C=S, or two adjacent radicals Y together form a chain; Q = X-NR 3 R 4, NR 5 -NR 6 -X-R 3, X-R 3, or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals; X = CH 2, CH(CH 3), CH, CO, CS; R 3 = hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl,methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl,thylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl, wherein Z A = hydrogen, halogen, cyano, or halomethyl (CF 3); R 4 = hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl; R 5 = H, alkyl, or haloalkyl; R 6 = H, alkyl, or haloalkyl; or wherein R 3 and R 4 together form a substituent selected from the group consisting of: and or a pharmaceutically acceptable salt thereof, wherein the composition is administered as a pour on and comprises a pharmaceutically acceptable carrier comprising at least one dermal penetration enhancer and a solvent system, wherein the dermal penetration enhancer comprises menthol, and the solvent system comprises a pyrrolidone solvent and a volatile solvent. R 1 = halogen, CF 3, OCF 3, or CN; n = integer from 0 up to and including 3; m = 1 or 2; R 2 = C 1 -C 3 haloalkyl; T = ring structure: 5-, or 6-membered, or bicyclic, which is optionally substituted by one or more radicals Y; Y = methyl, halomethyl, halogen, CN, NO 2, NH 2 -C=S, or two adjacent radicals Y together form a chain; Q = X-NR 3 R 4, NR 5 -NR 6 -X-R 3, X-R 3, or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals; X = CH 2, CH(CH 3), CH, CO, CS; R 3 = hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl,methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl,thylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl, wherein Z A = hydrogen, halogen, cyano, or halomethyl (CF 3); R 4 = hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl; R 5 = H, alkyl, or haloalkyl; R 6 = H, alkyl, or haloalkyl; or wherein R 3 and R 4 together form a substituent selected from the group consisting of: and or a pharmaceutically acceptable salt thereof, wherein the composition is administered as a pour on and comprises a pharmaceutically acceptable carrier comprising at least one dermal penetration enhancer and a solvent system, wherein the dermal penetration enhancer comprises menthol, and the solvent system comprises a pyrrolidone solvent and a volatile solvent. Z A = hydrogen, halogen, cyano, or halomethyl (CF 3); R 4 = hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl; R 5 = H, alkyl, or haloalkyl; R 6 = H, alkyl, or haloalkyl; or wherein R 3 and R 4 together form a substituent selected from the group consisting of: and or a pharmaceutically acceptable salt thereof, wherein the composition is administered as a pour on and comprises a pharmaceutically acceptable carrier comprising at least one dermal penetration enhancer and a solvent system, wherein the dermal penetration enhancer comprises menthol, and the solvent system comprises a pyrrolidone solvent and a volatile solvent.